The Trump administration launched TrumpRx, a website offering discounted prescription drug prices, on February 6, 2026, aiming to address the rising cost of medication. However, the program’s effectiveness hinges on individual circumstances, particularly for the 66% of Americans under 65 who have private health insurance, according to data from the Kaiser Family Foundation (KFF).
TrumpRx operates by offering prices based on the “most-favored-nation” (MFN) price – the lowest price paid in comparable countries – directly from manufacturers. The discounts are exclusively available to those paying in cash, explicitly stating on the website that the pricing is for “cash-paying” patients. Individuals with insurance are advised to compare the TrumpRx price with their insurance copay, as the latter may be lower.
The core challenge lies in the interplay between TrumpRx discounts and existing private insurance plans. For patients with insurance and no generic equivalent available, utilizing their insurance may ultimately be more cost-effective. Dollars paid for a TrumpRx medication will not count toward a consumer’s insurance deductible or out-of-pocket maximum. In contrast, payments made through insurance contribute to these thresholds, potentially lowering overall healthcare costs throughout the year. Negotiated prices through insurers or employer plans are also typically lower than the “wholesale acquisition cost” (WAC) used to calculate TrumpRx savings.
However, the increasing prevalence of high deductibles is prompting some insured individuals to explore self-pay options like TrumpRx. The average deductible for single coverage in employer-sponsored plans reached $1,663 in 2025, a 23% increase since 2020, according to KFF’s annual Employer Health Benefits Survey. For those who do not meet their annual deductible, the upfront cost of medication can be substantial, making the lower, albeit non-deductible applicable, TrumpRx price attractive.
The impact of TrumpRx also varies depending on plan design. 61% of workers enrolled in employer-sponsored health plans with a general annual deductible do not have to meet the deductible before prescription drugs are covered. 45% of covered workers in firms with 50 or more employees are enrolled in plans that reduce or waive cost-sharing for maintenance drugs for chronic conditions. These features can mitigate the financial incentive to bypass insurance for discounted self-pay options.
The availability of generic alternatives further complicates the equation. Approximately 90% of prescriptions filled in the U.S. In 2024 were for generics. In many cases, generic equivalents are cheaper than brand-name drugs, even after applying TrumpRx discounts. Analysis indicates that for about half of the drugs available on TrumpRx that have generic equivalents, those generics are less expensive through platforms like GoodRx or direct purchase from Cost Plus Drugs.
For individuals without insurance, or whose plans do not cover a specific drug, TrumpRx may offer genuine savings. For example, only 19% of large employers covered costly GLP-1 drugs like Wegovy and Zepbound for weight loss in 2025, and fewer than two in five (37%) covered fertility medications in 2024. However, some TrumpRx discounts are limited-time offers, such as an introductory price for Wegovy that increases after two months.
Manufacturer “copay assistance programs” also present a competing option for privately insured patients. These programs can reduce copays and coinsurance to $0 for some drugs, potentially negating the demand for TrumpRx discounts. However, many health plans do not count the value of these manufacturer coupons toward the enrollee’s deductible or out-of-pocket maximum, and at least 25 states and the District of Columbia have laws restricting the use of such programs.
As of February 24, 2026, TrumpRx includes discounts for 43 drugs. Consumers are advised to carefully compare prices and consider their individual insurance coverage and deductible status before opting for a TrumpRx discount.
